[SPAM] A stock Market Standout?

[Julian <club@xxxxxxxxxxxxxxxxxxxx>]

Worldwide Biotech & Pharmaceutical Company

SYMBOL: WWBP
Price: $3.73
On Aug 26: 3.73 up 0.73 (24.33%)

We gave you this at $2.00 eight trading days ago 
and we think its going to $12 in the next eight.

**THIS IS OUR SLEEPER PICK FOR 2005**
REASON WHY:
Worldwide Biotech & Pharmaceutical Company (OTC Bulletin Board: WWBP - News; "WWBP") 
has obtained the China Patent Golden Medal for "the Intact Hepatitis C Virus (HCV)" 
and Method for Culturing HCV in Vitro by Cell Culture.

1) About DAIYING
Yangling Daiying Biological Engineering Co., Ltd (OTC Bulletin Board: WWBP) ("DAIYING") 
is a hi-tech  biopharmaceutical company that specializes in the developing 
and marketing of viruses/viral vectors, in vitro diagnostics, Oral Solid Dosage Forms 
and prophylactic vaccines for humans. The company currently employs 86 Full Time Employees 
at 4 Chinese/US facilities.  Daiying's corporate headquarters, GMP-compliant manufacturing 
facilities and main laboratory are located 
in the Yangling Agricultural Hi-tech Industrial Demonstration Zone, Shan'xi Province, China.

2) Market Background
Hepatitis C Virus (HCV) is a small, enveloped, single-stranded RNA virus 
in the family Flaviviridae. HCV is a major cause of liver disease in the United States 
and the world. HCV accounts for about 15 percent of acute hepatitis cases, 60 to 70 percent 
of chronic hepatitis cases, and up to 50 percent of cases of cirrhosis, 
end-stage liver disease, and liver cancer. There about 1.3-2.5% of the worldwide population 
is infected with the virus. Almost 4 million Americans, or 1.8 percent of the U.S. population, 
have antibodies to HCV indicating ongoing or previous infection with the virus. 
In the United States, there are 150,000 newly infected cases. 
Approximately 10,000 to 12,000 deaths each year in the United States are due to HCV.

3) China has a population of 1.3 billion, of which 40 million are infected with HCV. 
Drawing analogy to the current HBV vaccination program, the number of people needing 
to be vaccinated should be 20-25% of the total population (several hundred million people). 
It is also possible the government will mandate immunization of high-risk populations such 
as drug users, health care workers, immno-deficient patients, and so on. 

4) HCV virus and antigen are needed by all research and development institutions 
that work with HCV, and the main market is comprised of major universities, 
medium-sized biotech and larger pharmaceutical companies, are close to 300 institutions. 
According to the market projection of DAIYING, the annual demand for HCV particles 
would exceed 150 million milliliters. With reference to that the vaccine virus samples 
from ATCC cost about $250.00 per milliliter with a $75.00 royalty fee. 
Assuming a 250ml single usage size, DAIYING expects to reach a gross sale 
of 300 million dollars each year (based on $200/ml).

World demand for is off the charts.
Which is why we are issueing a STRONG BUY FOR August 29.
We say put this (WWBP) on your screen and watch a major growth spurt.

The writers, PR firm, mailers involved in the creation, and distribution 
of the information above are not a registered broker/dealer and may not sell, 
offer to sell or offer to buy any security.  This profile is not a solicitation 
or recommendation to buy, sell securities. An offer to buy or sell can be made 
only with accompanying disclosure documents from the company offering or selling securities 
and only in the states and provinces for which they are approved. 
The material in this release is intended to be strictly informational and based 
on assumptions rather than fact. The companies that are discussed in this release 
have not approved the statements made in this release nor approved 
the timing of this release.  All statements and expressions are the sole opinion 
of the creators and are subject to change without notice. Information in this release 
is derived from a variety of sources including that company's publicly 
disseminated information, third parties and the writers research and optimistic speculation. 
The accuracy or completeness of the information is not warranted and is only as reliable 
as the sources from which it was obtained. All involved in the creation and distribution 
of this profile/release disclaims any and all liability as to the completeness 
or accuracy of the information contained and any omissions of material fact in this release. 
The release may contain technical and factual inaccuracies or typographical errors. 
It is strongly recommended that any purchase or sale decision be discussed 
with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. 
Investment in the securities of the companies' discussed in this release is highly speculative 
and carries a high degree of risk. All persons involved in the creation and distribution 
of the information in this letter is not liable for any investment decisions by its readers 
or subscribers. Investors are cautioned that they may lose all or a portion 
of their investment if they make a purchase in this security metioned. 
Any mention of past profiles and returns are not our stock picks

##### Don't be sorry next week that you forgot to buy this one! WWBP. #####

This profile is not without bias, and is a paid release. Writers and mailers 
have been compensated for the dissemination of company information on behalf of one 
or more of the companies mentioned in this release. Parties involved in the creation 
and distribution of this profile  have been compensated 50,000 dollars 
by a third party (third party), who is non-affiliated, for services provided including 
dissemination of company information in this release. PR and other individuals 
and other creators and mailers of this letter will sell all of its original shares 
during the distribution of this profile. Parties involved may immediately sell some 
or any shares in a profiled company held by profile creators and may have previously 
sold shares in a profiled company held by PR Individuals involved. 
Our Opt in mailing services for a company may cause the company's stock price to increase, 
in which event involved parties would make a profit when it sells its stock in the company. 
In addition, our selling of a company's stock may have a negative effect 
on the market price of the stock. The past profiles are only the winners 
not all of our recommendations.